The dopamine D 4 receptor has lately attracted interest since it has been hypothesized to be involved in the pathogenesis and pharmacotherapy of neuropsychiatric diseases. The present study provides first in vivo evidence of dopamine D 4 receptors in primate brain using a [ 11 C]benzo[g]quinoline, t
Dopamine D1 receptor imaging in the rodent and primate brain using the isoquinoline (+)-[11C]A-69024 and positron emission tomography
✍ Scribed by Laurent Besret; Frédéric Dollé; Anne-Sophie Hérard; Martine Guillermier; Stéphane Demphel; Françoise Hinnen; Christine Coulon; Michèle Ottaviani; Michel Bottlaender; Philippe Hantraye; Michael Kassiou
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 267 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
✦ Synopsis
In vivo pharmacokinetic and brain binding characteristics of (+)-[(11)C]A-69024, a high-affinity-D1-selective dopamine receptor antagonist, were assessed with micro-PET and beta-microprobes in the rat and PET in the baboon. The biodistribution of (+)-[(11)C]A-69024 in rats and baboons showed a rapid brain uptake (reaching a maximal value at 5 and 15 min postinjection in rats and baboons, respectively), followed by a slow wash out. The region/cerebellum concentration ratio was characterized by a fourfold higher uptake in striatum and a twofold higher uptake in cortical regions, consistent with in vivo specific binding of the radiotracer in these cerebral regions. Furthermore, this specific (+)-[(11)C]A-69024 binding significantly correlated with the reported in vitro distribution of dopamine D1-receptors. Finally, the specific uptake of the tracer in the striatum and cortical regions was completely prevented by either a pretreatment with large doses of nonradioactive (+/-)A-69024 or of the D1-selective antagonist SCH23390, resulting in a similar uptake in the reference region (cerebellum) and in other brain regions. Thus, (+)-[(11)C]A-69024 appears to be a specific and enantioselective radioligand to visualize and quantify brain dopamine D1 receptors in vivo using positron emission tomography.
📜 SIMILAR VOLUMES
The dopamine D-1 receptor antagonist, SCH 23390 ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3- benzazepin-7-ol), was labelled by alkylation of the desmethyl compound SCH 24518 ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-5-phenyl-1H-3-benzazepin-7- ol) with [11C]methyl iodide. A multivariate o
The cocaine analogue P-CIT-FE (N-(2-fluoroethyl)-2~-carbomethoxy-3~-(4-iodopheny1)nortropane) was labeled with ' lC for positron emission tomography (PET) studies of the dopamine transporter. After intravenous administration to a cynomolgus monkey, ["CIP-CIT-FE accumulated in the striatum with a str
Dexetimide (Fig. la), a potent muscarinic cholinergic receptor antagonist, and levetimide (Fig. lb), its pharmacologically inactive enantiomer, were labeled with "C for non-invasive in vivo studies of muscarinic cholinergic receptors in the human brain using positron emission tomography. The synthes
## Abstract Based upon data obtained with our arterio‐venous technique for the determination of cerebral metabolism in humans in vivo we have proposed a method for the determination of cerebral regional intermediary glucose metabolism in humans in vivo using specifically labeled ^11^C‐glucose and p